NCT04346628

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19

A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 149 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the efficacy of oral favipiravir plus standard of care treatment (SOC) compared with placebo plus SOC in reducing the duration of shedding of SARS-CoV2 virus in patients with mild or asymptomatic COVID-19.

Conditions

• Sars-CoV2
• COVID-19

Interventions

Type	Name	Description
DRUG	Favipiravir	Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).
DRUG	Placebo	Placebo to match favipiravir administered orally through day 10.
OTHER	Standard of care treatment	Standard of care treatment for COVID-19 infection

Timeline

• Start date: 2020-07-12
• Primary completion: 2021-04-16
• Completion: 2021-04-16
• First posted: 2020-04-15
• Last updated: 2022-07-13
• Results posted: 2022-04-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study